DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Actin...(er vaccine products said Robert N. Brey...),Health

Date:9/21/2009

er vaccine products," said Robert N. Brey, PhD, Chief Scientific Officer of DOR. "These new vaccines could be stored for long periods of time at ambient temperature, and avoid the current need for a well-controlled environmental cold chain. This would result in more useful vaccines for both civilian and military purposes."

"This grant award further validates the previous work and merits of our biodefense program," said Christopher J. Schaber, PhD, President and CEO of DOR. "We are very pleased that NIAID has chosen to support the development of a thermostable vaccine platform, as there are very few viable technology options at present that can effectively address heat stable vaccines. Our progress to date with RiVax(TM) has been impressive, and we believe that application of thermostabilization technology will accelerate the efforts to develop RiVax(TM) and other vaccines such as anthrax for potential use by the military and for the Strategic National Stockpile."

Dr. Schaber continued, "This $9.4 million grant puts our biodefense and vaccine business on solid footing and supports the necessary corporate infrastructure to continue to execute on these important programs."

About RiVax(TM)

RiVax(TM) is DOR's proprietary vaccine developed to protect against exposure to ricin toxin and is the most advanced vaccine in the company's portfolio. With RiVax(TM), DOR is the world leader in ricin toxin vaccine research. There are currently no vaccines available to prevent or treat ricin poisoning. The immunogen in RiVax(TM) induces a protective immune response in animal models of ricin exposure and consists of a genetically inactivated subunit ricin A chain that is enzymatically inactive and lacks residual toxicity of the holotoxin. One human Phase 1 clinical trial has been completed and a second trial is currently being conducted.

The development of RiVax(TM) has been sponsored
'/>"/>

SOURCE DOR BioPharma, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.75% Convertible Subordinated Notes Due August 16, 2023
2. Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
3. UK's Newcastle University Introduces First-Ever Biopharmaceutical Engineering Doctorate Program
4. PDL BioPharma to Present at BioCentury Newsmakers Conference on September 16, 2009
5. Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma
6. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
7. Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
8. PDL BioPharma Elects Barry Selick to Its Board of Directors
9. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
10. PDL BioPharma Announces Second Quarter 2009 Financial Results
11. PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009